Ekso Bionics Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Ekso Bionics Holdings Inc (EKSO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Ekso Bionics Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 11M vs 74M combined for tracked competitors (13.1% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-25.3% annualized vs trailing 12 months), vs decelerating (-18.8%) for its tracked peer group.
- Growth: Ekso Bionics Holdings Inc generated -26.1% revenue growth year over year in Q1 2026, vs -0.1% for its tracked competitors combined.
- Profitability: Its -332.0% net margin compares with -95.7% for the peer group.
- Peer revenue share: Ekso Bionics Holdings Inc accounted for 12.1% of combined revenue among its tracked peer group, down from 15.7% a year earlier.
- Peer differentiation: Revenue per employee of $0.36M compares with $0.13M for the peer group (2.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
EKSO Sales vs. its Competitors, Q1 2026
Ekso Bionics Holdings Inc reported revenue contraction of 26.09 % year on year in Q1 2026, below its competitors' combined revenue change of -0.07 %.
With a net margin of -331.97 %, Ekso Bionics Holdings Inc reported lower profitability than its competitors (-95.68 %).
Ekso Bionics Holdings Inc generated 12.13 % of the combined sales of its peer group, down from 15.73 % a year earlier.
Ekso Bionics Holdings Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Ekso Bionics Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Ekso Bionics Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Ekso Bionics Holdings Inc's competitor groups requires a Commercial License.
For context: the Industrial Machinery and Components industry grew revenue 12.4% year over year, combined, vs -26.1% for Ekso Bionics Holdings Inc. Ekso Bionics Holdings Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Ekso Bionics Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Ekso Bionics Holdings Inc | No | No | No | Yes |
| Competitors combined (2) | ||||
| High-Confidence Competitors (6) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 25.00 % (2 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EKSO Stock Performance relative to its Competitors
EKSO Stock Performance relative to High-Confidence Competitors
EKSO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Lifeward ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Ekso Bionics Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Ekso Bionics Holdings Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Ekso Bionics Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Ekso Bionics Holdings Inc | 42.04 | 11.11 |
| Lifeward ltd | 19.35 | 21.82 |
| Ss Innovations International Inc | - | 52.20 |
| SUBTOTAL | 61.40 | 85.13 |
Sources: Ekso Bionics Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Ekso Bionics Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Ekso Bionics Holdings Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Lifeward ltd | Named by the company | 85% |
| AlterG | Named by the company | 85% |
| Levitate | Named by the company | 85% |
| ReWalk Robotics | Named by the company | 85% |
| CoreWeave | Named by the company | 85% |
| Cyberdyne | Named by the company | 85% |
| Reha Technology | Named by the company | 85% |
| Nebius Group | Named by the company | 85% |
| Aretech | Named by the company | 85% |
| Ottobock | Named by the company | 85% |
| Skel-ex | Named by the company | 85% |
| Crusoe Energy | Named by the company | 85% |
| Hocoma | Named by the company | 85% |
| ReWalk | Named by the company | 85% |
| Myomo Inc | Named by the company | 85% |
| Bionik Laboratories | Named by the company | 85% |
| Parker Hannafin | Named by the company | 85% |
| SuitX | Named by the company | 85% |
| Lambda Labs | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Ekso Bionics Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Ekso Bionics Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Ekso Bionics Holdings Inc | 42 | 358,484 | -506,097 |
| Lifeward ltd | 19 | 269,407 | -380,617 |
| Ss Innovations International Inc | - | 108,071 | -24,835 |
| PEERS TOTAL | 19 | 131,242 | -75,931 |
Ekso Bionics Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Lifeward ltd | US 61.35 % |
| Ss Innovations International Inc | IN 98.66 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Ekso Bionics Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 128 companies in Ekso Bionics Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Ekso Bionics Holdings Inc ranks #0 of 128 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,578, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Asml Holding Nv | 702,552 | 32.04 % |
| 2 | Lam Research Corporation | 411,044 | 18.74 % |
| 3 | Deere and Co | 184,425 | 8.41 % |
| 4 | Eaton Corporation Plc | 169,834 | 7.74 % |
| 5 | Cae Inc | 1,234 | 5.2% |
| 6 | Bloom Energy Corporation | 1,234 | 5.2% |
| 7 | Illinois Tool Works Inc | 1,234 | 5.2% |
| 8 | Carrier Global Corporation | 1,234 | 5.2% |
| 9 | Ingersoll Rand Inc | 1,234 | 5.2% |
| 10 | Nvent Electric Plc | 1,234 | 5.2% |
| 0 | Ekso Bionics Holdings Inc | 42 | 0.00 % |
Market cap and industry share for the rest of Ekso Bionics Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-15.
Ekso Bionics Holdings Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Industrial Machinery and Components industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (166 companies). See the full Industrial Machinery and Components industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 55.01 % | 28.58 % (avg) | +26.4 pp |
| Operating Margin | -139.51 % | industry median | -146.2 pp |
| EBITDA Margin | -126.34 % | 3.86 % (avg) | -130.2 pp |
| Capital Intensity (Capex / Revenue) | - | 5.98 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Ekso Bionics Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Industrial Machinery and Components industry average (166 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Industrial Machinery and Components industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 33.3x | - |
| EV / EBITDA | - | 19.5x | - |
| P/B | 4.7x | 4.0x | +0.7x |
| Return on Equity | -197.81 % | industry aggregate | -213.28 % |
| Return on Invested Capital | -73.99 % | 1.28 % (avg) | -75.27 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Ekso Bionics Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 54.11 % | 22.81 % | -36.18 % | 26.62 % | 14.81 % | 40.02 % | -3.14 % | -32.36 % |
| Operating Margin | -238.53 % | -119.56 % | -149.64 % | -122.96 % | -120.48 % | -83.59 % | -59.73 % | -112.50 % |
| Return on Invested Capital | -133.74 % | -101.45 % | -88.50 % | -16.44 % | -24.09 % | -36.42 % | -30.38 % | -51.84 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Ekso Bionics Holdings Inc's Strategic Group Map
Every company in Ekso Bionics Holdings Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Ekso Bionics Holdings Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Ekso Bionics Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,578 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Ekso Bionics Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Ekso Bionics Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Ekso Bionics Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Ekso Bionics Holdings Inc falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Ekso Bionics Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 146.2 points below the industry median.
- Return on equity 213.3 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-25.3% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-18.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Ekso Bionics Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Ekso Bionics Holdings Inc | 0.39 | 1.76 | 0.34 |
| Lifeward ltd | 0.68 | 1.97 | 0.41 |
| Ss Innovations International Inc | 0.37 | 2.23 | 0.26 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Ekso Bionics Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Ekso Bionics Holdings Inc | Q1 2026 | -26.1 % | - |
| Lifeward ltd | Q2 2026 | +15.7 % | - |
| Ss Innovations International Inc | Q2 2026 | +39.4 % | - |
| PEERS TOTAL | +22.2 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Ekso Bionics Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Ekso Bionics Holdings Inc | Q1 2026 | +29.7 % | - |
| Lifeward ltd | Q2 2026 | +21.8 % | - |
| Ss Innovations International Inc | Q2 2026 | +67.4 % | +335,047.9 % |
Ekso Bionics Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Ekso Bionics Holdings Inc | - | - | - |
| Lifeward ltd | - | - | - |
| Ss Innovations International Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Ekso Bionics Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Ekso Bionics Holdings Inc | - | 3.78 |
| Lifeward ltd | - | 0.89 |
| Ss Innovations International Inc | - | - |
| PEERS AVERAGE | - | 0.72 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.